Holen Sie sich die Stockscreener-App
0.00
100.00%
-41.03
Schlusskurs vom Vortag:
$41.03
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$5.25B
Einnahmen:
$1.11B
Nettoeinkommen (Verlust:
$133.27M
KGV:
0.00
EPS:
1.0006
Netto-Cashflow:
$37.47M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$41.14
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
0.00 | 5.25B | 1.11B | 133.27M | 37.47M | 1.0006 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-13 | Eingeleitet | Roth Capital | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis (APLS) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading ; The Review Focuses on Reported ResultsEarnings Deceleration Risk - Vinanet
Wolfe Research Issues Rare Double Upgrade for Biogen and AbbVie, Setting $300 Targets - finance.biggo.com
Layoff Tracker: Sanofi cuts 229 Blueprint Medicines employees - BioSpace
new drugs are rewriting Biogen’s storyNews Freedom Broker - fbroker.kz
Biogen is scaling back acquisitions and will focus on its existing pipeline - medwatch.com
Biogen flips '26 guidance from expected decline to sales increase - Fierce Pharma
Biogen beats quarterly estimates as newer drugs drive growth - 1470 & 100.3 WMBD
Apellis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027 - Endpoints News
Biotech's takeover boom may be running out of buyers - Yahoo Finance UK
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover - MSN
Biogen projects $164M hit to Q2 results from R&D deals and acquisitions - MSN
Price to earnings forward of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Operating cash flow per share of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - MSN
Apellis Pharmaceuticals, Inc. Actuals & Estimates (LS:A2JAAW) - TradingView
A2JAAW Forecast — Price Target — Prediction for 2027 - TradingView
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work - Endpoints News
How Apellis Pharmaceuticals Inc. (APLS) Affects Rotational Strategy Timing - Stock Traders Daily
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Sullivan Timothy Eugene - Moomoo
Apellis Pharmaceuticals Inc (APLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal - Yahoo Finance
Apellis Pharmaceuticals Inc (APLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Apellis Pharmaceuticals Inc (APLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Apellis Pharmaceuticals Inc (APLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
EBIT per share of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Apellis Pharmaceuticals, Inc. (APLS) tops Q1 earnings and revenue estimates - MSN
Biogen (NASDAQ: BIIB) deems Apellis acquisition not significant - Stock Titan
Apellis Pharmaceuticals | SC TO-C: Written communication relating to an issuer or third party tender offer - Moomoo
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis (APLS) Amendment: Morgan Stanley Reports - Stock Titan
Number of shareholders of Apellis Pharmaceuticals, Inc. – BX:APLS - TradingView
APLS Technical Analysis & Stock Price Forecast - Intellectia AI
JP Morgan Maintains Apellis Pharmaceuticals (APLS) Overweight Recommendation - MSN
Apellis Pharmaceuticals (APLS) Holds Steady Near Support as Investors Weigh Catalyst PipelineTotal Put Call - po-news-eg.net
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
ViaSat, Innovative Solutions & Support, and Apellis Pharmaceuticals Lead Stock Performance - Markets Mojo
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - FinancialContent
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.42%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):